Phase 3 Alzheimer Disease trials recruiting now

All Alzheimer Disease trials, every phase

Other phases for Alzheimer Disease

Phase 3 Alzheimer Disease trials

• A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
  NCT06702124 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 159 locations
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 59 locations
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 293 locations
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 44 locations
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 252 locations
• Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
  NCT07115238 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Biomarker Exploration in Aging, Cognition and Neurodegeneration
  NCT03860857 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• Clinical Analgesic Management in Dementia
  NCT07323914 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 1 location
• Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
  NCT07062198 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 8 locations
• Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
  NCT07571161 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 30 locations
• Effect of CAFfeine on Cognition in Alzheimer's Disease
  NCT04570085 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 17 locations
• Epidemiology and Biomarker Study in Alzheimer's Disease
  NCT07142954 · Phase: Phase 3 · Ages: 55 Years to 75 Years · Sex: All (male and female) · 4 locations
• LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
  NCT07234695 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 5 locations
• Nabilone for Agitation Blinded Intervention Trial
  NCT04516057 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 6 locations
• PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
  NCT05456503 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
  NCT06254469 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · 1 location
• [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
  NCT06120049 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 4 locations
• [18F]PI-2620 Phase 3 Histopathological Study
  NCT05641688 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 25 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.